Ligand (LGND) Rule 144: JALAA Equities LP Sells 500 Shares

Ligand Pharmaceuticals, Inc. Rule 144 notice: JALAA Equities LP reported a sale of 500 common shares on 06/10/2026 for $124,980.42.

Rhea-AI Filing Summary

Ligand Pharmaceuticals, Inc. Rule 144 notice: JALAA Equities LP reported a sale of 500 common shares on 06/10/2026 for $124,980.42. The filing also shows 4,500 common shares linked to Wells Fargo Clearing Services with an Open Market purchase date of 04/28/2005.

Key Figures

Sold shares: 500 shares Proceeds: $124,980.42 Listed shares with broker: 4,500 shares +1 more

4 metrics

Sold shares 500 shares sale reported on <date>06/10/2026</date>

Proceeds $124,980.42 proceeds from the 500-share sale on <date>06/10/2026</date>

Listed shares with broker 4,500 shares associated with Wells Fargo Clearing Services, purchase date <date>04/28/2005</date>

Broker/Clearing firm Wells Fargo Clearing Services listed for 4,500 common shares

Key Terms

Rule 144, Open Market Purchase, Wells Fargo Clearing Services

3 terms

Rule 144 regulatory

"Rule 144 notice / Securities To Be Sold"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Open Market Purchase market

"Open Market Purchase | Open Market | 04/28/2005"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

Wells Fargo Clearing Services financial

"Wells Fargo Clearing Services 1 North Jefferson Avenue St. Louis MO"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the LGND Rule 144 filing report?

The filing reports that JALAA Equities LP sold 500 common shares of Ligand Pharmaceuticals on 06/10/2026 for $124,980.42. It also lists 4,500 common shares associated with Wells Fargo Clearing Services dated 04/28/2005.

Who executed the sale in the LGND Rule 144 notice?

The sale was reported by JALAA Equities LP, shown with an address in San Diego. The filing ties the traded security to Ligand Pharmaceuticals, Inc. and lists the transaction date as 06/10/2026.

How many shares and what proceeds are shown in the LGND filing?

The filing shows a disposition of 500 shares with proceeds of $124,980.42. Separately, 4,500 common shares are listed in a securities-to-be-sold row linked to Wells Fargo Clearing Services with a 04/28/2005 purchase date.

What selling method is noted in the LGND Rule 144 excerpt?

The excerpt shows an Open Market method for the 04/28/2005 entry and indicates the 500-share transaction is listed as a securities sold entry. Further distribution mechanics are not detailed in the provided excerpt.

Does the filing name the broker or clearing firm for the shares?

Yes; the filing lists Wells Fargo Clearing Services (1 North Jefferson Avenue, St. Louis, MO) in connection with 4,500 common shares. The 500-share sale is reported under JALAA Equities LP with its San Diego address.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 12:21 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001376960
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIGAND PHARMACEUTICALS INC
SEC File Number	001-33093
Address of Issuer	3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CALIFORNIA 92121
Phone	858-550-7500
Name of Person for Whose Account the Securities are To Be Sold	Aryeh Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Wells Fargo Clearing Services 1 North Jefferson Avenue St. Louis MO 63103	4500	1124879.82	20041061	06/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	04/28/2005	Open Market Purchase	Open Market			4500	04/28/2005	cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JALAA Equities LP 3911 Sorrento Valley Blvd. Suite 110 San Diego CA 92121	Ligand Pharmaceuticals, Inc.	06/10/2026	500	124980.42

144: Remarks and Signature

Remarks	shares were sold in account for JALAA Equities LP, Jason Aryeh as General Partner. 4,500 shares sold were acquired on 4/28/2005 and 4/29/2005.
Date of Notice	06/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jason Aryeh
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)